|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine|
|Rapid review commissioned||07/11/2012|
|Rapid review completed||19/11/2012|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.